Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

Fig. 3

Efficacy by BRCA mutation status. Representative BRCA mutations and PFS by BRCA mutation status in patients with ovarian cancer (A, B) and TNBC (C, D). Among 8 patients with gBRCAmut ovarian cancer, 5 had gBRCA1mut, 2 had gBRCA2mut and 1 had both gBRCA1mut and gBRCA2mut. Among 3 patients with gBRCAmut TNBC, all had gBRCA1mut. gBRCAmut, germline BRCA mutation; gBRCAwt, wild-type germline BRCA; PFS, progression-free survival; TNBC, triple-negative breast cancer

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us